SOAT1 and gastric cancer: Inhibitors abrogating the JAK-STAT pathway tested in pre-clinical and clinical studies have been recently extensively reviewed (4, 8, 15, 56, 71, 82, 220, 221) and so we will here focus on HNSCC/OSCC and GC.